REGULATORY INTELLIGENCE·Recall
Lupin Pharmaceuticals' Cefdinir Recall Highlights Critical Superpotency Risks and Supply Chain Vulnerabilities
Lupin Pharmaceuticals Inc. initiated a Class II recall of Cefdinir for Oral Suspension due to superpotency, stemming from out-of-specification assay results. This event, impacting 35,928 bottles nationwide, underscores persistent quality control challenges within the global pharmaceutical supply chain. Procurement and regulatory teams must scrutinize Lupin's manufacturing oversight and diversify sourcing strategies to mitigate future disruptions and ensure product integrity.
90-Day Activity